At 5 days post stroke, NaB-treatment reduced expression of brain IL-1beta (Fig. 6d, 123.0 ± 5.69 pg/mg protein vs. 97.05 ± 10.19 pg/mg protein, p = 0.0419, n = 11–12/group), IL-17A (Fig. 6e, 64.55 ± 8.79 pg/mg protein vs. 36.85 ± 8.39 pg/mg protein, p = 0.0344, n = 11–12/group), and IL-18 (Fig. 6f, 1911 ± 437.3 pg/mg protein vs. 907.8 ± 180.9 pg/mg protein, p = 0.0350, n = 11–13/group) in the ischemic hemisphere (cortex + striatum). The gene discussed is IL17A; the disease is stroke disorder.